Topic: Foreign Investment

JD Supra Corporate Brief: Health Care Acquisitions, Price Fixing Sentences, National Security Reviews, Collecting Whistleblower Awards

On this day in 1993, the Oslo Accords were signed in Norway between Israeli Prime Minister Yitzhak Rabin and Palestinian Liberation Organization Chairman Yasser Arafat. Just what the doctor ordered: a successful health care acquisition (DLA Piper) Fix prices and go to jail… (Foley & Lardner) Chinese investors can learn a lot from the 2013… Read more »

JD Supra Corporate Brief: Software Patents, China Investments, Employment Visas, FCPA Violations

Happy birthday, Atticus Finch: On this day in 1960, Harper Lee’s To Kill a Mockingbird was first published. Read it again to celebrate! What’s new in the world of software patents? Plenty! (K&L Gates) The Basel Committee wonders if international financial regulatory systems have become too complex. Really. (Shipkevich) Want to challenge a patent? Here… Read more »

Doing Business in China: Trade Secrets, Foreign Investment, Drug Safety Regulation, Consumer Data and Other Matters…

Laws to protect trade secrets in China have been around for nearly two decades, write attorneys in Orrick’s Trade Secrets Group. Nevertheless, the best way to protect your valuable corporate information is to never let it fall into the wrong hands: “Due to the difficulty proving and obtaining effective remedies for trade secret misappropriation, it… Read more »

Canada Changes Rules for Foreign Investment by State-owned Enterprises

“At the same time the government approved [the Progress Energy Resources and Nexen] acquisitions of control by Asian-based SOEs, the Prime Minister announced important changes to Canada’s policy for reviewing investments in Canada by state-owned enterprises which clearly indicate that the rules of the game for SOE investment have changed.” (Osler) Earlier this month, Canada’s… Read more »

Doing Business in China: A JD Supra Legal Reader

For your convenience, here’s a roundup of recent legal commentary and analysis on a broad range of issues facing companies doing business in and with China: Life Sciences Health Industry China Briefing – June 2012 (Reed Smith): “China’s new patent regulations allowing the government to force drug companies to grant compulsory licenses for generic versions… Read more »